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Abstract
The intentional re-introduction of Variola virus (VARV), the agent of smallpox, into the human population is of great concern
due its bio-terroristic potential. Moreover, zoonotic infections with Cowpox (CPXV) and Monkeypox virus (MPXV) cause
severe diseases in humans. Smallpox vaccines presently available can have severe adverse effects that are no longer
acceptable. The efficacy and safety of new vaccines and antiviral drugs for use in humans can only be demonstrated in
animal models. The existing nonhuman primate models, using VARV and MPXV, need very high viral doses that have to be
applied intravenously or intratracheally to induce a lethal infection in macaques. To overcome these drawbacks, the
infectivity and pathogenicity of a particular CPXV was evaluated in the common marmoset (Callithrix jacchus). A CPXV
named calpox virus was isolated from a lethal orthopox virus (OPV) outbreak in New World monkeys. We demonstrated
that marmosets infected with calpox virus, not only via the intravenous but also the intranasal route, reproducibly develop
symptoms resembling smallpox in humans. Infected animals died within 1–3 days after onset of symptoms, even when very
low infectious viral doses of 5610
2 pfu were applied intranasally. Infectious virus was demonstrated in blood, saliva and all
organs analyzed. We present the first characterization of a new OPV infection model inducing a disease in common
marmosets comparable to smallpox in humans. Intranasal virus inoculation mimicking the natural route of smallpox
infection led to reproducible infection. In vivo titration resulted in an MID50 (minimal monkey infectious dose 50%) of
8.3610
2 pfu of calpox virus which is approximately 10,000-fold lower than MPXV and VARV doses applied in the macaque
models. Therefore, the calpox virus/marmoset model is a suitable nonhuman primate model for the validation of vaccines
and antiviral drugs. Furthermore, this model can help study mechanisms of OPV pathogenesis.
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Introduction
After the worldwide vaccination program conducted by the
World Health Organization (WHO), smallpox was eradicated in
1980 [1], and soon after eradication general vaccination with
Vaccinia virus (VACV) against smallpox was discontinued. The
threat of intentional re-introduction of Variola virus (VARV), the
etiological agent of smallpox, into the human population by
terrorists remains of concern today because of the easy
transmission of the virus from person to person, a high mortality
rate after infection with the virus and the low or non-existent
smallpox immunity in the majority of the human population. Over
the last years an increasing number of humans infected with other
orthopox viruses (OPV) such as Cowpox (CPXV) and Monkeypox
virus (MPXV) was observed, indicating the zoonotic potential of
OPV species [2–5]. Outbreaks of MPXV have repeatedly been
reported from Central and Western Africa. In 2003, an outbreak
of human MPXV infection occurred in the mid-western United
States due to the inadvertent importation of MPXV by a shipment
of rodents from West Africa [3,6]. Although several squirrel
species are suspected to be natural reservoirs, the animal reservoir
for MPXV in Africa remains unknown [7]. In case MPXV were to
establish a reservoir status in a susceptible North American rodent
species such as prairie dogs [6,8], the consequences for public
health would be considerable.
CPXV seems to be limited to Europe and Central Asia with a
wide host range including humans [9,10]. CPXV is endemic in
wild rodents like bank voles (Clethrionomys glareolus) and wood mice
(Apodemus sylvaticus). However, CPXV is also sporadically detected
in rats (Rattus norvegicus) [11,12]. Domestic cats can become
infected by virus transmission from CPXV infected rodents and
are therefore commonly recognized as host for CPXV and are
responsible for the majority of human CPXV infections [13,14]. In
addition, CPXV has been isolated from a variety of zoo animals
[15–17]. Increasing travel activity and importation of exotic
animal species increase the risk of poxvirus transmissions outside
their usual geographical distribution. Therefore diagnostics might
often be delayed which has important implications.
The majority of these infections, particularly CPXV infections,
are mild and generally self-limiting with low morbidity. But
immunocompromised individuals may show a variety of compli-
cations including generalised infection and death [18,19]. On the
other hand, MPXV shows a significant morbidity and childhood
mortality in Africa [3].
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campaign in the USA in 2002. Persons with a potential risk of
OPV (VARV) exposure like military personnel and health-care
workers were vaccinated with the vaccine strain Dryvax. But as a
high rate of adverse effects associated with smallpox vaccination
has been observed, hardly any other country has recommended a
general vaccination against smallpox [20,21].
Consequently, research and development of new vaccines and
therapeutic agents for the prevention and treatment of poxvirus
infections is called for. During the period between vaccination and
antibody development protection against an OPV infection is not
ensured, neither does post-exposure vaccination necessarily
provide protection against a lethal infection [22,23]. Antiviral
therapies can fill this gap and thereby complement vaccination by
reducing viral load regardless of the immune status. Today, no
FDA-approved antiviral drugs for the treatment of orthopox virus
infections are available [23,24]. But some antiviral compounds like
Cidofovir and ST-246 showed an OPV-suppressing effect in cell
culture and, as therapeutic drug, in a variety of animal models
[25–27]. ST-246 was recently used very efficiently in the treatment
of a 2-year-old child with a severe eczema vaccinatum [28].
To license drugs or vaccines for prevention or therapy of human
infectious diseases like smallpox, these compounds must show
adequate protection in the case of a challenge with the pathogen in
one or more animal models. Based on this legislation, the United
States Food and Drug Administration (FDA) recommend the
testing of drugs or vaccines directed against such human diseases
in at least two animals, one using a non-rodent species. This
should ideally be a nonhuman primate. Although in vivo efficacy
and safety studies of vaccines and antiviral drugs should be done in
humans, this is not possible in the case of VARV/MPXV due to
ethical reasons. Therefore, nonhuman primates are used for the
testing of vaccines and antiviral compounds as these animals are
closely related to humans [29]. Currently the most common
animal models for studying the pathogenesis of OPV are the
Ectromelia virus (ECTV)/mouse model and the VACV/mouse
model. Infection with VARV and MPXV induces clinical disease
in two macaque species, i.e. cynomolgus (Macaca fascicularis) and
rhesus macaques (Macaca mulatta). However, these nonhuman
primate models suffer from major limitations: only high infectious
doses applied via an atypical route of infection reproducibly
induce a severe or lethal course of infection. In cynomolgus
macaques at least 10
8 plaque forming units (pfu) of VARV have to
be injected intravenously (i.v.) to induce a smallpox-like disease
[30], and rhesus macaques have to be inoculated intravenously
with at least 2610
7 pfu of MPXV to evoke symptoms [31,32]. For
the cynomolgus macaque/MPXV model different inoculation
routes like intravenous (i.v.), intranasal (i.n.), subcutaneous (s.c.)
and intratracheal (i.t.) application are described. But in this model
also high viral doses of 10
6–10
7 pfu are necessary for the induction
of smallpox-like symptoms, whereas animals that were given a
dose of ,10
6 pfu (i.n.) often survived depending on the MPXV
strain [23,32,33]. Although the clinical picture in this model is
similar to naturally acquired smallpox in humans where patients
survived depending on the virus strain, using non-lethal infection
models would not be sufficient to demonstrate the efficacy of newly
developed vaccines and therapeutic agents. Hence, a nonhuman
primate model with a lethal outcome would be advantageous.
Additionally, working with MPXV and VARV is methodologically
challenging, as bio-safety level (BSL) three or four conditions are
required. Moreover, macaques are relatively big animals and the
costs of maintenance are high compared to other animal models
for OPV infections. Therefore, the development of a safe and
reproducible OPV/nonhuman primate model which allows the
induction of a disease comparable to human smallpox is highly
recommended.
Thirty Callithrix as well as Tamarin monkey species died within
a week after onset of clinical symptoms in a colony of 80 New
World monkeys in a private zoo in Lower Saxony, Germany [34].
Histological and electron microscopical investigations revealed the
presence of OPV particles in different organs of deceased animals.
PCR and sequence analysis of selected genes confirmed these
findings and allowed a tentative grouping of this isolate to the
OPV species CPXV [34]. Samples from 6 of these animals were
available for laboratory confirmation. Virus isolation was
performed from skin tissue of deceased animals on Vero E6 and
Hep2 cells. The isolate was tentatively named calpox virus
according to its host Callithrix jacchus.
Here we describe the establishment of a new nonhuman
primate model for the study of OPV infections using the calpox
virus, a new CPXV, and the common marmoset Callithrix jacchus
which overcomes major limitations of existing primate models.
Results
Survival for different routes of infection
In order to determine whether the virus isolated was capable to
induce the disease observed during the natural outbreak, five
animals (group I) were inoculated intravenously (i.v.) with a viral
dose of 1.25610
7 pfu (animal I-a and I-b) or with 1.0610
7 pfu
(animal I-c, I-d and I-e). All animals died between day four and
day seven post infection (p.i.) (table 1). The symptoms observed
resembled those documented in the outbreak. As the i.v. virus
application resulted in a very rapid disease progression, only blood
samples at the time of death could be analyzed. High viral loads
with titers between 10
6 and 10
9 genome equivalents (GE)/mL
blood were measured (table 1).
After reproduction of the symptoms in marmosets by i.v.
inoculation of calpox virus, two other infection routes, i.e. the
oropharyngeal and intranasal (i.n.) inoculation were investigated.
An oropharyngeal inoculation was performed by applying
approximately 10
7 pfu of the virus next to the tonsillar region.
As only one out of five animals showed symptoms and died (data
not shown) it was decided to refrain from a more detailed
investigation of this infection route. For intranasal inoculation two
different virus preparations were investigated: a virus stock
prepared after three passages in Hep2 cells (virus stock A) and
the original cell culture isolate (virus stock B). Two marmosets
were inoculated with 2.3610
6 pfu (group II) (2650 ml, titer of
stock A 2.3610
7 pfu/mL) and two marmosets with 3.5610
5 pfu
(group III) (2650 ml, titer of stock B: 3.5610
6 pfu/mL).
All four marmosets died between day 9 and 10 p.i. (figure 1).
Blood samples were taken on day seven p.i. and at the time of
death. On day seven p.i. calpox virus was detected by real-time
PCR in three out of four animals (II-b, III-a, III-b) with viral loads
around 10
5 calpox virus GE/mL blood. At that time none of the
animals showed clinical signs of a disease. All four animals had a
final load of $10
6 calpox virus GE/mL blood at the time of death
(table 1). No difference in the course of infection was observed for
either virus preparation using the i.n. infection route.
Determination of calpox virus minimal lethal dose
To determine the MID50 (minimal monkey infectious dose
where 50% of the animals die) for the i.n. infection route, four
groups (group IV–VII) of two marmosets each were inoculated i.n.
with 3.5610
4, 3.5610
3,5 610
2 and 1610
2 pfu of calpox virus,
respectively.
OPV Infection Primate Model
PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e10412In animals of group IV (3.5610
4 pfu), group V (3.5610
3 pfu)
and in one animal of group VI (5610
2 pfu) the titer of calpox virus
in blood continuously increased from day seven p.i. onwards. All
five animals died on day 14 p.i. with high viral loads in blood
(table 1 and figure 1).
The second animal of group VI (5610
2 pfu) as well as both
animals of group VII (1610
2 pfu) did not become infected, as
defined by lack of clinical symptoms as well as viremia and
seroconversion within the observation period of 42 days. All three
surviving marmosets (animals VI-b, VII-a and-b) were re-
inoculated intranasally with 5610
2 pfu of calpox virus, resulting
in infection of one animal (VII-a) (table 1, re-inoculation). The
other two animals (VI-b and VII-b) did not show signs or markers
of infection during the pre-determined study time frame of 28 days
Table 1. Survival, calpox viral load in blood and tissues and seroconversion after intravenous and intranasal inoculation of
different doses of calpox virus.
animals virus inoculation
detection
of
symptoms
survival
[days
p.i.]
viral load in blood [[calpox GE per1
ml blood]/[calpox mRNA copies per
10
6 c-myc mRNA copies]
a IgMb viral load in tissue
c
group no. route dose [pfu] day p.i.
day detect-
able p.i.
initial
viral load
final
viral load
tissues with
#10
5 tissues with $10
7
intravenous inoculation
I a i.v. 1.25610
7 4n a n a 4 . 2 610
8/3.5610
7 — sk, he, lu, li, sp, ln
b 6 na na 3.3610
9/1.4610
8 — sk, he, lu, li, ki,
sp, ln, bl, si, es
c i.v. 1.0610
4 5n a n a 1 . 0 610
6/5.1610
6 — bl, st, es, si,
co, br
sk, lu, li, sp
d 7 na na 8.0610
8/4.9610
7 — sk, lu, li, sp, ln
e 7 na na 6.9610
8/2.5610
7 — si sk, lu, li, sp, ln, es
intranasal inoculation
II a i.n. 2.3610
6 10 10 nd/nd 4.0610
6/3.8610
7 — bl, st, si, co, br sk, sp, es, to
b 9 7 4.0610
5/4.5610
7 1.4610
8/3.8610
7 — si, co, es, br sk, lu, sp, ln, to
III a i.n. 3.5610
5 9 7 1.7610
5/1.4610
7 9.7610
7/1.2610
8 — si, co, br sk, lu, sp, tr
b 9 7 8.9610
4/6.9610
6 3.6610
7/3.1610
8 — bl, si, co, es sk, sp, to
intranasal calpox virus titration
IV a i.n. 3.5610
4 14 14 7 9.5610
3/3.2610
4 1.3610
9/3.5610
7 — he, bl, si sk, lu, ki, sp, ln
b 11 14 7 1.5610
4/2.2610
5 2.2610
9/2.1610
8 — si, br sk, he, lu, li, ki,
sp, ln, tr
V a i.n. 3.5610
3 11 14 7 1.1610
4/5.6610
4 2.8610
7/1.9610
8 + es, co, br sk, lu, sp, ln
b 14 14 10 nd/nd 3.5610
7/1.1610
8 + he, bl, st, si,
co, br
sk, ln
VI a i.n. 5.0610
2 14 14 7 2.7610
2/7.3610
2 1.3610
8/7.3610
7 + bl, br sk, lu, li, sp, ln, tr
b none 42
d nd nd/nd nd/nd — na na
VII a i.n. 1.0610
2 none 42
d nd nd/nd nd/nd — na na
b none 42
d nd nd/nd nd/nd — na na
A re-inoculation of animals VI b, VII a and b
e
VI b i.n. 5.0610
2 none 28
d nd nd/nd nd/nd — na na
VII a 14 14 7 1.9610
5/1.7610
5 3.6610
7/1.1610
7 — sk, lu, li, sp, ln, es
VII b none 28
d nd nd/nd nd/nd — na na
B2
nd re-inoculation of animals VI b and VII b
e
VI b i.n. 3.5610
3 10 12 7 4.4610
4/4.2610
6 2.1610
9/2.8610
6 — st, si sk, lu, li, sp, ln
VII b none 28
df nd nd/nd nd/nd — all tissues tested
were negative
acalculation of the copy numbers for both, calpox virus and c-myc is based on the mean value of duplicate measurements and a respective quantified plasmid standard
for each real-time PCR assay.
bseroconversion, detection of IgM antibodies in plasma by immunofluorescence assay at the time point of death or at pre-determined end of experiment (surviving
animals).
cviral load was expressed as calpox GE/10
6 c-myc genomic DNA; all tissues that were analyzed are indicated, from infected animals all tissues tested were positive. Viral
load was defined as low=equal or below 10
5GE, or high=equal or above 10
7GE. Tissue abbreviations: sk: skin; he: heart; lu: lung; li: liver, sp: spleen, ki: kidney; ln:
lymph node (axillaris, mesenterialis, submandibularis); bl: bladder; st: stomach; es: esophagus; si: small intestine; co: colon; br: brain; to: tonsils; tr: trachea.
dpre-determined endpoint of experiment for animals without sign of infection.
eanimals not infected during previous experiment(s) were re-infected.
fanimal was sacrificed at end of experiment.
i.v.: intravenous, i.n.: intranasal; na: no sample available; nd: not detectable; the detection limit for both assays was 10 copies; GE: genome equivalents (genomic DNA).
doi:10.1371/journal.pone.0010412.t001
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3.5610
3 pfu. One of the two animals (VI-b) became infected and
died on day 12 p.i. with approximately 10
9 calpox GE/mL blood.
Animal VII-b survived without developing any clinical symptoms,
and neither calpox virus nor antibodies against OPV were
detected in blood or tissue at necropsy (table 1, 2
nd re-inoculation).
Using the VACMAN 3.1 program [35], the MID50 of calpox
virus was calculated. This program is generally used for statistical
analysis of primate trials working with very small animal numbers
as well as virus dilutions other than 1:10 for virus titration.
Standard statistical analysis programs do not take into account the
effect of all the experimental imponderabilities inherent in this
model, like virus dilution, virus stability or genetic variation
between animals. At a dose of 5610
2 pfu corresponding to a virus
stock dilution of 1:700 two out of five animals died, reaching the in
vivo endpoint of calpox virus via the i.n. route. From this data an
MID50 of 8.3610
2 pfu of calpox virus was estimated.
Reproducibility of infection with 10 MID50
The number of animals used for in vivo titration was too small to
statistically support the data. Therefore, we infected six marmosets
i.n. with a lethal dose of ten MID50, corresponding to
8.3610
3 pfu. All six animals died between day 12 and 15 p.i.
(figure 1). Calpox virus DNA was detectable in the blood of all
marmosets as early as day seven p.i., and the copy numbers rapidly
increased towards death to final values of 10
9 calpox GE/mL
blood (data not shown).
Clinical observations
Intravenous virus inoculation induced clinical symptoms like
breathing difficulties, languishment and anorexia in five of five
animals (100%) only one day before death. Macroscopic
inspection of all deceased animals revealed few small papular skin
lesions with a diameter of 2–3 mm on face, breast and inner sides
of the thighs, which were often accompanied by focal hemor-
rhages. After i.n. inoculation the first clinical signs of infection
(breathing difficulties, nasal discharge, languishment and anorexia)
were similar to i.v.-infected animals and also appeared only one to
two days before death. Characteristic of all i.n.-infected animals
were edema with focal and petechial bleeding in the larynx and/or
thorax area and multiple skin lesions scattered on face, abdomen
and thighs as well as edema in the larynx. Lymph nodes draining
the areas of the skin lesions were marked by severe lymphatic
hyperplasia (further description of the pathology will be publish
elsewhere). Quality and timing of clinical symptoms were
independent of the viral dose and appeared one to two days
before death. There was no recovery from the disease after virus
was detected in blood (regarded as successful infection).
Determination of calpox virus load in different tissues
High levels of calpox virus DNA were detectable by quantitative
real-time PCR in all tissues collected from all deceased marmosets
independent of the route of infection or viral dose (figure 2 A
shows an example for i.v. inoculation, table 1). The highest viral
loads were measured in skin, spleen, lung, lymph node, tonsils and
trachea (between 10
7 and 10
8 calpox virus GE/10
6 c-myc GE).
Lower viral loads were generally found in bladder, stomach, small
intestine, esophagus, colon and brain (10
4–10
5 calpox virus GE/
10
6 c-myc GE) (table 1). In agreement with the data from viral
DNA quantification, the highest RNA expression levels of calpox
virus with up to 10
7 calpox virus mRNA copies/10
6 c-myc mRNA
copies were found in lung, spleen, lymph node and skin
(exemplarily shown for group I (i.v.) in figure 2 B), and the lowest
calpox virus mRNA copy numbers were found in stomach, small
intestine, esophagus and colon (,10
4 calpox virus mRNA copies/
10
6 c-myc mRNA copies). For both inoculation routes the highest
viral loads were observed in lymphoid organs, indicating a
progressive infection and replication of the virus in these organs,
Figure 1. Kaplan-Meier plot showing the effect of different
doses of calpox virus inoculated intranasally (i.n.) on the
survival of marmosets. Survival post infection (p.i.) is expressed as
percentages. Ratios given on the right side indicate numbers of
surviving animals versus numbers of animals inoculated. Doses as low
as 8.3610
3 pfu led to 100% mortality.
doi:10.1371/journal.pone.0010412.g001
Figure 2. Distribution of calpox virus in different tissues. Virus
was determined in different tissues of infected animals and is shown
exemplarily for i.v. infected animals of group I determined by real-time
PCR. A) calpox virus genome equivalents (GE) (viral DNA copy number)/
10
6 c-myc GE (DNA copy number of cellular gene marker); B) calpox
virus mRNA copies/10
6 c-myc mRNA copies; calculation of the copy
numbers for calpox virus as well as c-myc is based on the mean value of
duplicate measurements and a respective plasmid standard for each
real-time PCR assay; lines indicate the median value for all 5 i.v.-infected
marmosets (group I); GE: genome equivalents.
doi:10.1371/journal.pone.0010412.g002
OPV Infection Primate Model
PLoS ONE | www.plosone.org 4 April 2010 | Volume 5 | Issue 4 | e10412whereas calpox virus replicated less efficiently in organs of the
digestion tract and the brain.
Electron microscopy revealed typical brick-shaped mature and
immature OPV virus particles in various tissues (figure 3, section
B) also confirming successful infection. Infectious virus was
quantified in tissues, using the plaque assay, and compared to
the results obtained by quantitative PCR using the same tissue
preparation and normalized to 1 mL tissue homogenate. Infec-
tious calpox virus was detected in all tissues. The infectious virus
titer of a tissue was about three to five logs lower than the titer of
GE for all inoculation doses (figure 4 A, results of animal V-a
infected with 3.5610
3 and VI-a 5610
2 pfu are shown as
examples).
Serology
Plasma samples of all virus-inoculated animals were screened for
IgM and IgG antibodies, using an immunofluorescence assay, as
well as for neutralizing antibodies, using a plaque reduction
neutralization test (PRNT). After i.v. or i.n. infection with high
doses of virus, no virus-specific antibodies could be found. This
was expected as a surviving time of approximately 10 days p.i. is
too short for developing OPV-specific antibodies.
Three out of eight marmosets inoculated with lower doses of
calpox virus (animals V-a, V-b and VI-a) seroconverted with
maximal IgM antibody titers of 1:80 that were only detectable at
the time of death at 14 days p.i. (figure 3, section A). Neither IgG
nor neutralizing antibodies were detectable in any of the animals
(data not shown). Supposedly, all infected animals died before the
development of a specific IgG antibody response.
Viral load in saliva
To investigate whether virus transmission could occur via
droplets from aerosolized saliva, throat swabs and blood samples
were collected simultaneously and analyzed for infectious calpox
virus. The appearance of infectious calpox virus in saliva was
delayed by approximately three days when compared to that in
blood and was first detectable on day 10 (figure 4 B) in the
majority of the animals which became infected and had survived
up to this point in time. The amount of infectious virus per throat
swab was difficult to normalize because the volume of saliva
collected could not be quantified (saliva in throat swab was
resolved in 300 ml D-MEM medium). In addition, the saliva was
not cell-free and in consequence cell-associated virus might have
been co-detected. However, infectious calpox virus titers increased
parallel to viral loads in blood, reaching the highest levels at the
time of death (figure 4 B). These results underline a potential virus
transmission from animal to animal via virus-containing droplets
as it has been described in naturally occurring smallpox infection
in man.
Discussion
As already shown for other nonhuman primate models
[30,31,36], the i.v. inoculation route is a non-physiological route
of infection which bypasses the mucosa and circumvents a primary
replication of the virus in regional lymph nodes and the successive
systemic spread via the lymphatic system, altogether representing
the first viremia. Since the natural disease progression is altered in
i.v. inoculation models [29], it is unclear how antiviral efficiency
tested in i.v. models correlates with antiviral efficacy in naturally
occurring human diseases. As human VARV infection normally
occurs via airborne transmission, the i.n. calpox virus application
was established in common marmosets mimicking this major
natural route.
Here we demonstrated that the calpox virus isolate could
produce a lethal disease in common marmosets which in a variety
of features resembles smallpox rather than CPXV infection in
humans, i.e., an airborne generalized lethal infection with lesions
Figure 3. Analysis of antibodies and virus particles in infected animals. Section A: Determination of orthopox virus-specific IgM antibodies.
IgM antibodies were determined in the serum of infected marmosets at the time of death (day 14 p.i.), calpox virus-infected Hep2 cells were
incubated with serum (1:10 diluted) and visualized with anti-human IgM-FITC labeled antibody, 1:63 magnification; A1) negative serum; A2) animal
V-a; A3) animal VI-a, bars correspond to 20 mm; Section B: Electron micrographs of mature and immature calpox virus particles in different tissues of
animal V-b; B1) immature virus particles in liver tissue; B2) mature virus particles in lung tissue and B3) immature virus particles in spleen tissue;
arrows indicate virus particles.
doi:10.1371/journal.pone.0010412.g003
OPV Infection Primate Model
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infection usually occurring through skin lesions. Furthermore, in
contrast to other OPV/nonhuman primate models, a low dose
(MID50 of 8.3610
2 pfu) of cell-free virus applied i.n. reproducibly
infected the animals even only statistically insufficient animal
numbers were used for the determination of the MID50. Ten
MID50 corresponding to 8.3610
3 pfu led to a lethal infection in all
animals. The onset of clinical symptoms depended on the viral
dose whereas the symptoms themselves were dose independent
and generally appeared very shortly before death. There was no
recovery from the infection in any of the animals when virus was
detected in blood as well as after onset of symptoms. Furthermore,
all animals lacking any clinical signs also failed to show markers of
infection like antibodies against OPV antigens or detection of viral
genomes by PCR. It seems like the immune response in marmosets
is altered. Seroconversion is delayed and was only seen in three out
of eight marmosets which survived up to 14 days p.i. This is in
contrast to naturally occurring non-hemorrhagic smallpox infec-
tions in humans where IgG antibodies titers were detectable about
18 days p.i., respectively [37]. Moreover, after i.v. or i.n. infection
with high doses of calpox virus, no virus-specific antibodies could
be found. This is explained by the short surviving time of
approximately 10 days p.i. which is probably too short for
developing OPV-specific antibodies. Similar observations like
delayed, reduced or even failing antibody response are reported
for hemorrhagic-type smallpox patients [38]. In humans generally
a sub-lethal infection results in the production of a protective
immune response. This was not seen for the calpox virus/
marmosets model. Due to the lack of statistical support of the data
the alteration of the marmoset immune response after calpox virus
infections needs further investigation.
Infectious calpox virus was found in the saliva of all diseased
marmosets, with kinetics similar to those in blood. Therefore, the
intranasal inoculation caused a clinical outcome probably capable
of spreading the virus via a natural route of transmission among
other animals before clinical symptoms became apparent – the
same route of virus transmission that applies to human smallpox
infection.
Independent of infection route and inoculated viral dose, high
copy numbers of virus genomic DNA and virus-specific mRNA
Figure 4. Detection of calpox virus in tissues and saliva. A) comparison of infectious calpox virus titer and calpox virus genome equivalents
(GE) per ml tissue homogenate for two animals infected with 3.5610
3 (V-a) and 5.0610
2 pfu (VI-a) (line indicates the median value for animals V-a and
VI-a); for real-time PCR: calculation of the copy numbers for calpox virus is based on the mean value of duplicate measurements and a respective
plasmid standard; B) infectious calpox virus in saliva (normalization approximated by using throat swab as the denominator) compared to GE in
blood (during course of infection) for three different infectious doses (group IV: 3.5610
4, V: 3.5610
3 and VI: 5.0610
2 pfu); pfu: plaque forming unit;
p.i.: post infection; GE: genome equivalents.
doi:10.1371/journal.pone.0010412.g004
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organs and tissues, showing the wide cell tropism of calpox virus.
The general involvement of multiple organs is similar to lethal
human MPXV and VARV infections where virus is found in
various organs [38]. The massive virus replication across all organs
was probably associated with organ dysfunction and multisystem
failure already shown for VARV infections in cynomolgus
macaques [30].
In the calpox virus/marmoset model the time period between
onset of clinical signs and death of the marmosets appears to be
foreshortened compared to human smallpox. In contrast to
severely diseased humans infected with VARV or MPXV
[4,38,39–41], only a limited number of small skin lesions were
observed and sparingly scattered over the bodies of the test
animals, independent of the infection route. In other nonhuman
primate models the number of skin lesions is part of the clinical
score and points towards the disease outcome. This is different in
the marmoset model although all infected marmosets developed
skin lesions. However, all infected animals developed a clinically
apparent infection which always resulted in the death of the
animals. In no case was recovery from the disease observed. This is
in contrast to the natural infection with VARV and MPXV, where
only a fraction of the patients with clinical signs of infection had a
lethal outcome [41]. Animals surviving inoculation of very low
doses of calpox virus showed neither immunological nor
virological markers of an infection, suggesting no take of the
virus. A clinical score for the signs of illness defining the severity of
the infection might be helpful and important, but does not seem to
be necessary in the marmoset model in which any clinical
symptom ends up in a lethal outcome. The readout for success or
failure of any prophylactic or therapeutic interventions is simply
the death rate in the respective study arm after viral exposure,
making assessments of any measure much easier compared to
other nonhuman primate models or in other animal models.
A weakness of other OPV nonhuman primate models is that the
virus has to be administered in very high doses to induce fatal
disease [23,33,42–44]. In contrast, the MID50 of calpox virus is
approximately 10,000 times lower than that determined in other
nonhuman primate model for OPV infections. An exception is the
cynomolgus monkey/MPXV model where inhalation of 10,000 to
148,000 pfu of aerosolized MPXV in a modified Henderson head
only exposure chamber induced lethal infection. However,
technical and safety measures for this approach are considerable.
Moreover, a successful infection with calpox virus is reproducibly
achieved when 10 MID50 (8.3610
3 pfu of calpox virus) are
administered intranasally. The low MID50 and the i.n. inoculation
route used in the calpox virus/marmoset model mimic naturally
acquired VARV and MPXV infections in humans.
Furthermore, epidemiologic investigations of the natural calpox
virus outbreak in the colony of New World monkeys [34] gave no
evidence of transmission of the virus to humans (Broll et al.,
unpublished). Experimental work with calpox virus, tentatively
grouped to the OPV species CPXV, can be done under BSL-2
conditions. Advantages of the marmoset model over other
nonhuman primate models include the small size of the animals,
reasonably sized housing space and conditions, easy handling, a
high reproduction rate in captivity, their inexpensive keeping, their
economic purchase price and the fact that no wild populations are
endangered [44]. Moreover, the common marmoset has already
been used as a model for a wide spectrum of experimental research
on human diseases [45–51].
Summarized, the calpox virus/marmoset model is an important
addition and alternative to the primate models for OPV infection
currently used because it overcomes the limitations of these models
like the requirement of high viral doses applied by an unnatural
route. Therefore, it is a valuable and suitable tool to evaluate the
efficacy of new vaccination strategies and antiviral therapies for
the prevention or treatment of human OPV infections.
Materials and Methods
Ethical statement
Marmosets (Callithrix jacchus) were bred and housed at the
German Primate Centre under standard conditions according to
the German Animal Welfare Act which complies with the
European Union Directive 86/609/ECC and the European
Union guidelines on the welfare of non-human primates used in
research.
The study was performed in accordance with the regulations of
the German Animal Protection Law. This includes statement of
the responsible animal welfare officer of the German Primate
Centre and authorization by the regional governmental veterinary
authorities. The authorization process implies the hearing of the
application and ethical judgement by an independent animal
protection board which is composed of six persons from animal
protection organisations and scientific community. The experi-
ments were supervised by local governmental veterinary author-
ities. The approvals by the governmental veterinary authorities of
Lower Saxony, Germany, have the reference numbers: 33.11.425-
04-019/07; 33.425027/08-07.05; 33.42502/08-02.04.
All animals were inspected twice per day by the veterinarians of
the German Primate Centre. In cases of suffering animals were
treated with analgetic drugs or otherwise the experiment was
stopped by humane killing with subsequent post mortem analysis.
Animals, virus inoculation and sampling
Two to six years old adults of either sex were used. Housing
conditions were 25uC, 60% humidity and single cages
(130 cm653 cm680 cm) for each animal, with acoustical contact
to each other. For virus application marmosets were anesthetized
by injecting 0.1 mL of a mixture of 1 mg xylazine (RompunH,
Bayer AG, Leverkusen, Germany), 5 mg atropine (Boehringer,
Ingelheim, Germany), 5 mg ketamine (KetalarH, Parke-Davis,
USA) per 200g body weight into the hamstring muscle. Calpox
virus was administered i.v. in a maximal volume of 500 ml into the
vena saphena. Oropharyngeal virus application was performed by
dropping 100 ml virus-containing saline close to the tonsillar
region. Intranasal infection was carried out as described elsewhere
[52,53] by pipetting 50 ml virus-containing saline into each nostril.
Blood was collected under ketamine anesthesia by puncture of the
femoral vein at regular intervals. Faucal swabs were obtained by
swabbing the deeper pharyngeal area with a cotton-wool swab
saturated with phosphate buffered saline (PBS). Thereafter, the
swab was squeezed out in 300 ml DMEM medium and the fluid
stored at 280uC until further use.
Virus and cells
Calpox virus was propagated in Hep2 cells (ECACC: 86030501)
in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) with 5%
fetal calf serum and 1% glutamine at 37uC in a 5% CO2
humidified atmosphere. Infected cells were incubated for approx-
imately four days until a pronounced cytopathic effect was
observed. Supernatant and cells were harvested from infected
cultures. After freeze-thawing and intensive vortexing with glass
beads for better cell disruption the suspension was centrifuged for
10 min at 200 g to pellet the cell debris. The virus-containing
supernatant was overlaid onto a 30% sucrose cushion and
ultracentrifuged for 3 h at 3.4610
3 g. The pelleted virus was re-
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0.5 mL/tube). The infectivity titer of the calpox virus stock was
determined by a plaque assay on Vero E6 (ECACC 85020205)
cells grown in DMEM supplemented with 10% fetal calf serum
and 1% glutamine. Virus titers were expressed as plaque forming
units (pfu) per mL.
Isolation of calpox virus DNA and RNA from whole blood
50 or 100 ml EDTA blood was used for DNA extraction using the
QIAamp viral Blood Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s protocol. DNA was eluted in the same volume as
the initial blood volume. For the isolation of RNA from blood a
preceding erythrocyte lysis step was performed with a red cell lysis
buffer (0.144 M NH4Cl, 1 mMNaHCO3 in H2O). RNA from blood
cells was isolated using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) following the manufacturer’s instructions. To avoid DNA
contamination in RNA samples, a DNA digestion was additionally
performed for 40 min at 37uC using the Ambion TURBO DNase
Kit according to the manufacturer’s protocol (Ambion, Applied
Biosystems Business, Darmstadt, Germany).
Isolation of calpox virus DNA and RNA from tissues
Tissue samples of a defined weight were homogenized in PBS
using the FastPrep machine (MP Biomedicals, Eschwege,
Germany). Aliquots of 100 ml homogenates were used for RNA
and DNA extraction and for plaque assay. For the preparation of
total DNA from tissue the QIAamp viral Blood Kit and for total
RNA preparation the RNeasy Mini Kit was used. Similar to RNA
extraction from blood cells a DNA digestion was performed for
40 min at 37uC using the Ambion TURBO DNase Kit according
to the manufacturer’s protocol (Ambion, Applied Biosystems
Business, Darmstadt, Germany) to avoid DNA contamination in
RNA samples. RNA was tested for DNA contamination by
performing cDNA syntheses without reverse transcriptase followed
by a c-myc real-time PCR.
cDNA was generated by reverse transcription (RT) in a total
volume of 20 ml containing 10 ml RNA, 500 ng calf thymus DNA
(Sigma Aldrich, Hamburg, Germany), 500 ng oligo dT(18) primer
(Metabion, Martinsried, Germany) which was incubated at 65uCf o r
5 min before adding 4 ml5 6buffer,2 ml 0.1 M DTT, 0.4 ml2 5m M
dNTP and 200 U Superscript II (Invitrogen, Karlsruhe, Germany).
Afterwards samples were incubated at 37uC for 50 min and at 70uC
for 10 min. For each RNA sample a negative RT reaction was
performed in which the reverse transcriptase Superscript II was
replaced by water to prove that the obtained RNA was DNA free.
Determination of viral load by real-time PCR
For virus detection and quantification a calpox virus-specific
real-time PCR assay (forward:59-gTCTTTCTCgTTTAC-
CAAgTgC; reverse:59- ACAgAgAAAACATTTAAggATgAATC-
TATA; mgb-probe:Fam-TAgCTCCgTTTATTTTgTTA-NQ-
mgb) was established. It showed no cross reactivity to other
orthopox viruses, which might be important for later vaccination
experiments. A c-myc-specific real-time PCR (forward:59-gCCA-
gAggAggAACgAgCT; reverse:59-ggg CCTTTTCATTgTTTT-
CCA; probe: 59-FAM-TgCCCTgCgTgACCAgATCC-TAMRA)
was used for relative quantification to standardize the number of
cells in the samples. For absolute real-time PCR quantification the
amplicons of the target regions for calpox virus and c-myc were
cloned into a TOPO-TA vector (Invitrogen, Karlsruhe, Ger-
many). Plasmids were quantified in a photospectrometer and 10-
fold serial dilutions were used for calibration curves. All samples
were measured in duplicate for both assays. The mean value of
both CT values was used for calculation of the copy numbers. Viral
DNA quantities were expressed as calpox virus genome equiva-
lents (GE) per mL blood or per 10
6 copies of the c-myc gene for
tissue samples. The calpox virus mRNA copy numbers were
calculated per 10
6 c-myc copies, too. For all real-time PCR assays
the PlatinumTaq polymerase (Invitrogen, Karlsruhe, Germany)
was used.
Plaque assay
Infectious calpox virus in saliva and tissue homogenates was
determined by plaque assay and expressed as pfu per mL. Briefly,
tenfold serial dilutions of the samples (100 ml) were incubated with
100 ml of a Vero E6 cell suspension for 4 hours at 37uC and 5%
CO2 in 24-well plates. After incubation cells were overlaid with
200 ml 1.6% carboxymethylcellulose (CMC) and incubated for
another four days. Cell supernatant was aspirated and cells were
fixed in 1 mL 3.7% formaldehyde for 30 min, stained with
naphthalene blue black (1 g naphthol blue black [Sigma-Aldrich,
Deisenhofen, Germany], 13.6 g sodium acetate, 60 mL glacial
acetic acid [both Merck, Darmstadt, Germany], ad 1 l ddH2O) and
washed once with water. The virus titer (pfu/mL) was calculated
based on plaque numbers counted for each dilution step.
Plaque reduction neutralization test (PRNT)
Plasma and serum samples were incubated for 30–60 min at
56uC to inactivate virus and/or complement. Twofold serial
dilutions of the plasma samples were mixed with an equal volume
of calpox virus. After an incubation for 1 h at 37uC and 5% CO2,
100 ml serum–virus mixture was added to pre-seeded Vero E6 cells
in 100 ml cell culture medium. Virus was allowed to adsorb for 1 h
at 37uC and 5% CO2. Cells were overlaid with 200 ml of 1.6%
CMC and incubated for further four days at 37uC and 5% CO2.
Medium was aspirated and fixation and staining of cells were done
identically to the plaque assay. The number of plaques/well was
counted and the titer for 50% plaque reduction was calculated in
comparison to the virus titer obtained for negative marmoset
serum which served as control.
Immunofluorescence assay
To detect virus-specific antibodies in the plasma of infected
marmosets, plasma samples were heat treated for 30–60 min at 56uC
to inactivate virus as well as complement components. Subsequently,
slidescoatedwithcalpoxvirus-infectedHep2cells(fixedwithacetone)
were incubated for 1 h at 37uC with twofold serial dilutions of
plasma. For IgM determination IgGs were removed using Mastsorb
absorb (Mast Diagnostica, Reinfeld, Germany) before the plasma was
incubated with the antigen. After two washing steps with 16PBS a
goat anti-human IgG FITC-labeled antibody (for IgG determination)
or goat anti-human IgM FITC-labeled antibody (for IgM determi-
nation) (both Caltag, Burlingame, CA, USA) was used as second
a n t i b o d y .E v a n sB l u e( S i g m a - A l d r i c h ,D e i s e n h o f e n ,G e r m a n y )w a s
added to stain the cytoplasm of the cells. Slides were analyzed by
fluorescence microscopy.
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